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Congenital infection with Trypanosoma cruzi is a global problem, occurring on average in 5% of children born 
from chronically infected mothers in endemic areas, with variations depending on the region. This presentation aims 
to focus on and update epidemiological data, research methods, involved factors, control strategy and possible pre-
vention of congenital infection with T. cruzi. Considering that etiological treatment of the child is always effective if 
performed before one year of age, the diagnosis of infection in pregnant women and their newborns has to become 
the standard of care and integrated into the surveillance programs of syphilis and human immunodeficiency virus. 
In addition to the standard tests, polymerase chain reaction performed on blood of neonates of infected mothers one 
month after birth might improve the diagnosis of congenital infection. Recent data bring out that its transmission 
can be prevented through treatment of infected women before they become pregnant. The role of parasite genotypes 
and host genetic factors in parasite transmission and development of infection in foetuses/neonates has to be more 
investigated in order to better estimate the risk factors and impact on health of congenital infection with T. cruzi.
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At least two million women in fertile age are estimat-
ed to be chronically infected with Trypanosoma cruzi in 
Latin America with the incidence of congenital infec-
tion being at least 15,000 cases/year (OMS/OPS 2006). 
Maternal-foetal transmission may be repeated in each 
pregnancy (family clustering of congenital cases) and 
can occur from one generation to another (vertical trans-
mission) [reviewed in Carlier and Truyens (2010)].
Since congenital infection with T. cruzi (i) is cur-
rently mostly silent (asymptomatic), (ii) may progress to 
severe chronic Chagas disease later in life and (iii) can 
be effectively cured if treated [with benznidazol (BZ) 
or nifurtimox (NFX)] within the first year of life, its di-
agnosis is of upmost importance. A consensus has been 
established on the control strategy to be applied and gold 
standards for its laboratory diagnosis have been recom-
mended (Carlier et al. 2011).
The testing process begins by identifying pregnant 
women living or who have lived in endemic areas or 
having received blood transfusion or organ transplants 
in endemic areas or who were born to an infected moth-
er, assuring they are really infected. T. cruzi-specific 
antibodies are identified using two serological tests. 
Conventional tests, such as ELISA, indirect immun-
ofluorescence and indirect haemagglutination, whose 
performance depends on good quality testing kits and 
good laboratory practice, have been in use since 1975 in 
all endemic countries. Rapid tests can be used but need 
to be confirmed by standard serological tests. Tests can 
be performed during pregnancy (prenatal) or on umbili-
cal cord blood (containing transferred maternal IgG an-
tibodies) (Sosa-Estani et al. 2008). If the test results are 
negative, there is no possible transmission.
After confirmation of infection in the mother, para-
sites have to be sought in the newborn from close-to-
birth up to one month after birth using parasitological 
tests (e.g. micro-haematocrit, haemoculture) if resources 
exist in the health systems and/or by serological methods 
after eight months of age when maternal transferred IgG 
antibodies have disappeared. If parasites are observed 
(microscopic examination) or specific antibodies are 
detected after eight months, infection is proved and the 
infant should be treated (Fig. 1).
This presentation aims to focus on and update epide-
miological data and research methods on congenital in-
fection with T. cruzi, the factors involved in parasite trans-
mission and development of infection in foetuses/neonates 
and its control strategy and its possible prevention.
Present situation of congenital infection with T. cruzi/
congenital Chagas disease in endemic and non-en-
demic countries.
Although both terms are often confused, “congenital 
infection with T. cruzi” refers to asymptomatic as well 
as symptomatic cases of infection, whereas “congenital 
Chagas disease” is mainly used to describe symptomatic 
cases. The maternal-foetal transmission rate, classically 
defined as the number of congenital cases/number of T. 
cruzi-infected mothers (Carlier & Truyens 2010), can 
gain in precision if expressed as the number of congeni-
tally infected infants divided by the number of infants 
born to infected mothers (including multiple births) 
(Howard et al. 2014).
Although maternal-foetal transmission of T. cruzi 
occurs in an average of 5% of chronically infected moth-
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ers (the most frequent clinical form of Chagas disease) in 
endemic areas, major differences seem to occur among 
the different countries. The largest surveys have been 
performed in endemic countries located in the South 
Cone of Latin America. For example, congenital T. cruzi 
infection was detected in 431 of 7,188 children in Argen-
tina (6%), in 292 of 7,086 in Bolivia (4.1%) and in 115 of 
2,691 in Paraguay (4.3%) (Howard et al. 2014). Studies 
from Brazil and other endemic countries include shorter 
series. Nevertheless, in a survey performed from 2004-
2012 in the state of Goiás (GO) in Brazil 910 of 1,773 
pregnant women (51.3%) were confirmed as seropositive 
for T. cruzi and only eight of 894 (0.9%) delivered an 
infected newborn (AO Luquetti, unpublished observa-
tions). In a larger seroepidemiological study (performed 
from 2001-2008) of 104,813 children under five years 
old and living in vector-free areas (detected infection is 
here considered to be congenital) of all Brazil, only 20 
(as well as their mothers) were infected (0.02%), 12 of 
them coming from a single state (Rio Grande do Sul), 
bordering Argentina and Paraguay (Table) (Luquetti et 
al. 2011). A recent systematic review of Brazilian data 
from 1984-2009 indicates a pooled congenital transmis-
sion rate of 1.7% (Martins-Melo et al. 2014), i.e., less 
than in the American South Cone countries.
Congenital transmission has also been recorded from 
non-endemic countries as a consequence of migration of 
infected pregnant women from Latin America (mainly 
Bolivia), in the United States of America, Spain, Swit-
zerland and Sweden. From the 18 studies performed in 
Spain, 32 children from the 743 born to infected mothers 
were found infected (4.3%) and in another study from 
Switzerland two children were infected from eight [re-
viewed in Howard et al. (2014)].
Whether the local variations in the distribution of 
congenital infection with T. cruzi are due to the different 
methods used to detect it or to known or still unknown 
factors involved in transmission and/or development of 
congenital Chagas disease (see below), well-framed large 
population-based studies are needed to better measure 
its frequency, risk factors and impact on health.
Epidemiologic research methods for field studies of 
congenital T. cruzi infection/congenital Chagas disease
Different epidemiologic designs can be used to study 
congenital T. cruzi infection at the population level. Ap-
proaches include (i) prospective cohort studies, measur-
ing maternal antibodies during prenatal care or on um-
bilical cord blood and following-up the infants (Buekens 
et al. 2013), (ii) case-control studies comparing cases 
with rare outcomes to healthy controls and retrospective-
ly assessing if their mothers were T. cruzi infected and 
(iii) cross-sectional studies, which are often household 
surveys (Gamboa-León et al. 2014). Point-of-care rapid 
tests and tests performed on dried blood spots on filter 
papers facilitate the serological testing in the field.
In cohort studies, challenges to identify T. cruzi in-
fected infants include having trained personnel available 
24/7 to perform direct parasitological examination of 
cord blood and of infants’ blood obtained by heel prick 
within a few hours after blood collection, and organis-
ing follow-up household visits to perform T. cruzi serol-
ogy after the disappearance of maternal antibodies after 
eight months of age. Mobile Health approaches to con-
tact mothers by cell phone and geographic information 
systems are helpful to facilitate household visits.
Factors involved in maternal-foetal transmission of 
T. cruzi infection and development of congenital 
Chagas disease
Four main factors (parasite, mother, placenta, foetus) 
are involved in the transmission and/or the development 
of congenital Chagas disease. Since the transmission of 
TABLE
Distribution of children congenitally infected with  








Alagoas 3,742 1 0.03
Bahia 16,577 2 0.01
Minas Gerais 11,386 3 0.03
Paraná 3,424 1 0.03
Pernambuco 7,140 1 0.01
Rio Grande do Sul 4,569 12 0.26
a: data from the national survey of seroprevalence, Brazil 2001-
2008 (Luquetti et al. 2011); b: number of confirmed congenital 
cases after venous collection of blood of the child and the respec-
tive mother by four different serological tests; c: proportion of 
the final number of confirmed cases of congenital transmission 
(areas free of vector transmission) among the number of samples 
collected in filter paper from children below five years of age.Fig. 1: decision algorithm in the control strategy of congenital infec-
tion with Trypanosoma cruzi.
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parasites through breast feeding (postnatal), amniotic 
fluid or by transuterine route are unlikely (Virreira et al. 
2006b, Carlier & Truyens 2010, Norman & López-Vélez 
2013), the haematogenous transplacental route is the only 
possibility for prenatal or perinatal transmission.
Role of parasite - The capacity of parasites to invade 
placental cells (see below), as well as their virulence and 
amount in pregnant women (particularly in retroplacen-
tal blood), is doubtless involved in their maternal-foetal 
transmission, as likely are their virulence and amount in 
the development of congenital Chagas disease in foetus-
es/neonates. It remains to be determined if such features 
depend on parasite genotypes as defined today. Indeed, 
various genotypes of T. cruzi (TcI, TcII, TcIII, TcV and 
TcVI) and associations of different genotypes have been 
identified in cases of congenital infection. The genotype 
TcV has been reported in 80-100% of congenital cases in 
Argentina, Bolivia, southern Brazil, Chile and Paraguay, 
whereas TcII has been identified in the few cases de-
tected in the other Brazilian states (Virreira et al. 2006a, 
2007, Burgos et al. 2007, Corrales et al. 2009, Garcia et 
al. 2014, AO Luquetti et al., unpublished observations); 
so, whether e.g. TcI, TcII or other genotypes are transmit-
ted less frequently and involved less in the development 
of congenital infection remains to be investigated.
Role of parasitaemia and immune status of pregnant 
women - Parasitaemia increases during pregnancy (2nd 
and 3rd trimesters) and high maternal parasitaemias are 
associated with congenital transmission (Hermann et al. 
2004, Virreira et al. 2007, Brutus et al. 2010, Siriano et 
al. 2011, Bua et al. 2012). Indeed, transmission occurs in 
nearly 100% of pregnant women with reactivated infec-
tions [as, e.g., in case of co-infection with human im-
munodeficiency virus (HIV)] (Scapellato et al. 2009), 
in 53% of acute infection during pregnancy (8/15 of re-
ported cases) (Brabin 1992, Moretti et al. 2005) and in 
roughly 5% of chronic infection in endemic countries, 
displaying huge, high and hardly detectable parasitae-
mias, respectively (Fig. 2).
Maternal-foetal transmission of parasites is also as-
sociated with some degree of maternal immune defi-
ciency: a lower innate immune response with reduced 
leukocyte release of tumour necrosis factor (TNF)-α 
(García et al. 2008) and a lower T-cell-mediated specific 
type 1-immune response with reduced production of in-
terferon (IFN)-γ (Hermann et al. 2004), that likely con-
tribute to increased maternal parasitaemia.
Why can transmission be repeated in each preg-
nancy or be transgenerational (see above)? Are there 
predisposed mothers with a reduced capacity of T-cell-
mediated response? These unanswered questions should 
encourage studies on the possible role for host genetic 
factors favouring parasite transmission.
Role of placental defences and route of transmission 
- The presence of parasites in intervillous blood induces 
the release by placenta of proinflammatory cytokines, 
chemokines, as well as reactive oxygen and nitrogen inter-
mediates that are susceptible to kill parasites (Díaz-Luján 
et al. 2012). However, in vitro studies show that T. cruzi 
can infect and multiply within human villous trophoblas-
tic cells (Shippey et al. 2005, Castillo et al. 2013).
What are the lessons of the histopathologic studies of 
placentas from infected foetuses/neonates? Roughly, two 
situations have been observed: (i) in severe and mortal 
congenital Chagas disease (rare today, but frequent in 
the past), a severe placentitis/villitis occurs with destruc-
tion and rupture of the trophoblastic barrier; parasites are 
found in villous trophoblast and stromal cells, cytokines, 
such as TNF-α, are intensively produced and, in such 
cases, the placental innate defences are likely overflowed 
by huge parasitaemias in the intervillous space (it is prob-
ably what occurs also in experiments in vitro); the rup-
ture of the trophoblastic barrier further increases foetal 
infection and TNF-α contributes to abortion and neonatal 
mortality (Bittencourt 1988, Altemani et al. 2000); (ii) in 
mild congenital T. cruzi infection in live neonates (fre-
quent today), villitis is much less marked or not observed, 
parasites are not or hardly identified in villous trophoblast 
(Moya et al. 1979, Azogue et al. 1985, Altemani et al. 
2000, Fernandez-Aguilar et al. 2005, Carlier & Truyens 
2010) and this indicates that trophoblast remains a barrier 
for T. cruzi, and haematogenous transmission to foetuses 
has to take alternative transplacental routes.
What are the possible alternative transplacental 
routes? Two can be identified: (i) the placental marginal 
zone (joining the membranes to the chorionic and basal 
plates, constituted of smooth muscle cells embedded in 
an extracellular matrix, only covered by a nontrophoblas-
tic epithelium); serial biopsies performed in 19 placentas 
from infected live Bolivian newborns showed the den-
sities of parasites were particularly high and gradually 
decreased in the chorionic plate and distant membranes 
inducing chorionitis/chorioamnionitis; (ii) the placental 
breaches/tears appearing naturally close to the pregnancy 
term (labour contraction-mediated damages) (Fernandez-
Aguilar et al. 2005, Carlier & Truyens 2010).
Fig. 2: maternal-foetal transmission rates in acute (AI), chronic (CI) 
and reactivated (RI) Trypanosoma cruzi infection.
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Parasites enter the chorion and, surviving the mes-
enchymal second placental line of defence, spread by 
successive infections of fibroblasts and macrophages to 
finally gain access to foetal vessels embedded in chori-
onic plate and umbilical cord.
Parasitaemia and immune status of foetuses/neonates 
- Morbidity and mortality of congenital Chagas disease 
are associated with high parasitaemias, i.e., rely on the ca-
pacity of transmitted parasite to multiply into the foetus/
neonate (virulence). Asymptomatic congenital cases gen-
erally display at birth less than 100 p/mL in blood while 
100-1,000 p/mL can be found in symptomatic cases and 
the rare lethal clinical forms can reach up to 125,000 p/mL 
(Torrico et al. 2005, Virreira et al. 2007, Bua et al. 2012).
This raises the question of the capacity of foetuses/
neonates to control infection despite their alleged immu-
nological immaturity. Both innate and adaptive immune 
responses have been observed in foetuses/neonates. In-
flammatory responses are induced in uninfected neo-
nates born to T. cruzi-infected mothers (Vekemans et al. 
2000, García et al. 2008, Cuna et al. 2009) and neona-
tal dendritic cells (Rodriguez et al. 2012), natural killer 
cells (Guilmot et al. 2014) and monocytes (Guilmot et 
al. 2013) can be activated by T. cruzi. The capacity of 
activated monocytes to eliminate parasites opsonised by 
transferred maternal antibodies might protect offspring 
of infected mothers against the development of congeni-
tal infection (capacity of self-cure?) (Truyens & Carlier 
2010). Moreover, infected foetuses/neonates display ac-
tivated and cytotoxic CD8 T cells that produce IFN-g in 
response to parasites (Hermann et al. 2002). However, 
such specific capacity to produce IFN-g is drastically 
reduced in neonates displaying high parasitaemias, i.e., 
in severe and lethal forms of congenital Chagas disease 
(Torrico et al. 2005), indicating that immune defences 
are either lacking, insufficient or initiated too late in 
congenitally infected neonates and become unable to 
control multiplication of parasites transferred from their 
mother. Altogether these data strongly suggest that most 
current congenital infections with T. cruzi result from: 
(i) weak maternal innate and adaptive type 1 immune 
responses enhancing parasite multiplication and high 
parasitic loads in retroplacental blood, (ii) an haematog-
enous route of parasite transmission through placental 
areas deprived of trophoblast and (iii) insufficient foe-
tal/neonatal innate defences and parasite-specific type-1 
immune response to control multiplication of transmit-
ted parasites. Therefore, whether parasites in maternal 
blood can be either not transmitted (there is no congeni-
tal infection in case of sufficient maternal immune re-
sponses) or transmitted to the foetus with the subsequent 
development of a congenital Chagas disease (in case of 
weak foetal/neonatal immune response), the possibility 
of transmission followed by a rapid elimination of para-
sites by the foetal immune responses cannot be excluded 
(in this case of self-cure, there would be a brief congeni-
tal infection without development of congenital Chagas 
disease). More investigations are needed to specify the 
role of parasite genotypes in such mechanisms and of 
host genetic factors governing the intensity of immune 
responses towards parasites.
Prevention and control of congenital T. cruzi infection/
congenital Chagas disease
The control strategy of congenital infection de-
fined above (Carlier et al. 2011) can be improved by 
analysing why opportunities for its proper diagnosis 
are lost in health systems.
Analysis of losses of opportunities of adequate diag-
nosis of congenital infection - In the health system, such 
losses can be due to: (i) low attendance to prenatal care 
for diagnosing infection in pregnant women (low prior-
ity for health systems), (ii) low rate of infection detec-
tion by parasitological tests or (iii) health workers do not 
know the procedures, do not have adequate training and 
do not have good working conditions. At the community 
level, mothers do not know the procedure and/or do not 
understand the instructions and/or do not have financial 
resources to travel to the health centres.
Potential solutions in health systems and communities 
- T. cruzi serology has to be integrated in national or lo-
cal programs of prenatal screening with syphilis and HIV. 
Such surveillance has to become the standard of care. If 
prenatal screening is not possible, serological diagnosis 
has to be performed at delivery. Information, education 
and communication programs on Chagas disease and its 
congenital transmission have to be strengthened at the 
community level. Some successful programs in two states 
of Brazil (Mato Grosso do Sul and GO) are currently un-
derway (Botelho et al. 2008, Siriano et al. 2011).
Tests to improve timely laboratory diagnosis of con-
genital infection - More experience has been accumulat-
ed using polymerase chain reaction (PCR) for diagnosis 
of congenital T. cruzi infection. In addition to its known 
higher sensitivity over parasitological methods when 
used at birth (Virreira et al. 2003, Mora et al. 2005), 
PCR performed repeatedly at different time points af-
ter birth has been shown to allow an earlier diagnosis of 
congenital infection [positive PCR are mainly obtained 
1.5 months after birth, whereas the micro-haematocrit 
tests are positive at an average of 6.7 months and serol-
ogy at 11.8 months (Velázquez et al. 2014)]. PCR detects 
more infected children at 30 days after birth, when para-
site burden is at its maximum (Bua et al. 2012, 2013). 
Moreover, using PCR one month after birth rather than 
at birth might reduce the risk of false positive diagno-
sis in case of transmission of parasite DNA debris from 
mother or self-cure by the foetus/neonate (see above).
Detection of antibodies against shed acute-phase 
antigen (SAPA) in maternal and offspring blood seems 
promising to identify congenital T. cruzi infection within 
30 days after birth, when the mother is SAPA nonreac-
tive and the child is SAPA reactive or when the differen-
tial of SAPA using matched samples of mother and child 
is ≥ 1. In contrast, the offspring does not have congenital 
T. cruzi infection when the child is SAPA nonreactive 
or both samples of the mother and child are reactive, 
but with a differential < 1 (Mallimaci et al. 2010, Rus-
somando 2010). However, experience using detection of 
SAPA antibodies for the diagnosis of congenital T. cruzi 
infection remains limited to Paraguay and Argentina 
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and would need the availability of reagents and to be ex-
tended to other areas before being recommended.
Prevention of congenital infection is possible - Re-
cent results have shown the benefit of trypanocidal 
treatment in girls or nonpregnant women to prevent con-
genital transmission to their newborns (Sosa-Estani et 
al. 2009, Fabbro et al. 2014). Three hundred fifty-four 
nonpregnant women living in urban areas of Argentina 
and infected with T. cruzi were followed during 16 ± 
eight months: 132 were treated with BZ (5 mg/kg/day) 
or NFX (10 mg/kg/day) for 30-60 days and 222 had not 
received treatment. Children born to these mothers were 
investigated for occurrence of congenital transmission 
of T. cruzi by standard methods. Analysis of results indi-
cated that children of untreated women (34 infected out 
of 222) have 21 times more risk of congenital infection 
with T. cruzi than children born to women treated be-
fore pregnancy (0 infected out of 132), indicating that the 
etiological treatment of infection before pregnancy is an 
effective strategy for primary prevention of congenital T. 
cruzi infection/Chagas disease.
Concluding remarks
Congenital transmission of T. cruzi is a global prob-
lem, occurring on average in 5% of children born from 
chronically infected mothers in endemic areas, with 
variations depending on the region. Since the diagnosis 
tools used can at least partially explain such variations, 
larger population-based studies using similar methods 
are needed to better measure the frequency of congenital 
T. cruzi infection/Chagas disease. A better knowledge of 
the factors involved in its transmission and development 
and particularly the role of parasite genotypes and host 
genetic factors, should allow a better estimation of its 
risk factors and impact on health outcomes. Considering 
that etiological treatment of the child is always effective 
if performed before one year of age, the diagnosis of in-
fection in pregnant women and their newborns is man-
datory. In addition to the standard tests, PCR performed 
on blood of neonates of infected mothers one month af-
ter birth might improve such diagnosis. The availability 
of more simple and accurate diagnostic methods easily 
implemented in primary health care settings could pro-
vide tools for the timely treatment of infected newborns. 
Additionally, evidences are showing that congenital 
transmission could be prevented through treatment of 
infected women before they become pregnant.
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